<DOC>
	<DOCNO>NCT02092571</DOCNO>
	<brief_summary>A study ass pharmacokinetics 2 progesterone vaginal ring postmenopausal woman</brief_summary>
	<brief_title>A Pharmacokinetic Study Evaluate Bioequivalence 2 Progesterone Vaginal Rings Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Progesterone</mesh_term>
	<criteria>Inclusion : 1 . Naturally postmenopausal woman intact uterus , 40 70 year age , inclusive . 2 . The subject serum estradiol FSH level consistent subject postmenopausal . 3 . The subject clinically significant abnormality finding observe pelvic , breast , vaginal examination base mammogram Pap smear evaluation . 4 . The subject agree treat 1 mg/day estradiol oral tablet least 28 day insertion first vaginal ring throughout study . Exclusion : 1 . The subject history presence significant cardiovascular , pulmonary , hepatic , renal , hematologic , gastrointestinal , endocrine , urologic , gynecologic , immunologic , dermatologic , neurologic , psychiatric disease . 2 . The subject history toxic shock syndrome . 3 . The subject history jaundice associate previous use oral contraceptive . 4 . The subject contraindication use estrogen progesterone include , limited , following : know sensitivity estrogen progesterone related drug know hypersensitivity study medication ingredient , include FD &amp; C Yellow No . 5 ( tartrazine ) present estradiol tablet undiagnosed vaginal bleeding high risk endometrial cancer breast mass examination know , suspect , family history estrogen progesteronedependent neoplasia ( past ) 5 . The subject lowgrade squamous intraepithelial lesion ( LSIL ) bad observe Pap smear screening . Any abnormal finding Pap smear investigator considers clinically significant ( atypical squamous cell exclude highgrade squamous intraepithelial lesion [ HSIL ; ASCH ] , atypical glandular cell [ AGC ] ) ; Pap result would necessitate evaluation biopsy and/or colposcopy . 6 . The subject abnormal find condition deem clinically significant investigator screen contraindication use progestin , estrogen , vaginal ring . 7 . The subject positive pregnancy test screening time study . 8 . Current treatment progesterone , progestin , estrogen ( estradiol 1mg tablet , progesterone 200mg capsule , medroxyprogesterone acetate 10mg tablet require study purpose ) . 9 . Use following medication within time frame note start estrogen treatment : vaginal hormonal product ( ring , cream , gel ) within 7 day transdermal estrogen alone estrogen/progestin product within 28 day oral estrogen progestin therapy within 56 day intrauterine progestin therapy within 56 day progestin implant estrogen alone injectable drug therapy within 3 month estrogen pellet therapy progestin injectable therapy within 6 month 10 . The subject vaginal ultrasonography screen confirms active endometrial lining and/or endometrial thickness â‰¥4 mm .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>